+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Differentiation of human umbilical cord blood CD133+ stem cells towards myelo-monocytic lineage



Differentiation of human umbilical cord blood CD133+ stem cells towards myelo-monocytic lineage



Clinica Chimica Acta; International Journal of Clinical Chemistry 343(1-2): 85-92



Characterisation of stem cells by flow cytometry, their expansion and differentiation are presently of major interest for cell engineering as the basis of a therapeutic concept for transplantation. Haematopoietic stem cells (HSC) express CD34, the adhesion structure which binds 2L-selectin, CD117, a receptor for stem cell factor (SCF; c-kit ligand), and CD133, a transmembrane protein belonging to the family of mucoproteins. The aim of the present investigation was the systematic investigation of proliferation and differentiation characteristics of umbilical cord blood stem cells (UCBSC) isolated by an immmunomagnetic separation system using CD133 antibody-coated microbeads and to evaluate the effects of different sera and various concentrations, as well as the effects of IL-3 and IL-6 on total cell expansion and differentiation of isolated CD133+ cells. Differentiation patterns were measured by flow cytometry. After the immmunomagnetic separation the yield of CD133+ cells was 0.45+/-0.17 x 10(6) cells/ml; the purity of isolated CD133+ cells was 95.79+/-1.86%. The majority of CD133+ cells coexpressed CD117. The most pronounced expansion during cultivation of 2 weeks was achieved in media supplemented with 12.5% horse serum plus 12.5% fetal calf serum (FCS) with stem cell factor and interleukine 3; the fold-expansion was 16.67+/-6.20. During the cultivation period, UCBSC were constantly loosing stem cell markers and differentiated towards myelo-monocyte lineage (granulocytes and/or monocytes). These in vitro results demonstrate that thorough investigation of various cultivation conditions is needed for successful expansion and differentiation of stem cells towards different lineages to be used therapeutically for replacement of damaged cells.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011960137

Download citation: RISBibTeXText

PMID: 15115679

DOI: 10.1016/j.cccn.2003.11.019


Related references

Human umbilical cord blood-derived stromal cells are superior to human umbilical cord blood-derived mesenchymal stem cells in inducing myeloid lineage differentiation in vitro. Stem Cells and Development 21(9): 1429-1440, 2012

In Vitro Differentiation of Human Umbilical Cord Blood CD133(+)Cells into Insulin Producing Cells in Co-Culture with Rat Pancreatic Mesenchymal Stem Cells. Cell Journal 17(2): 211-220, 2015

Down-regulation of CD105 is associated with multi-lineage differentiation in human umbilical cord blood-derived mesenchymal stem cells. Biochemical and Biophysical Research Communications 381(4): 676-681, 2009

The Effect of Baicalin as A PPAR Activator on Erythroid Differentiation of CD133(+)Hematopoietic Stem Cells in Umbilical Cord Blood. Cell Journal 17(1): 15-26, 2015

Platelet growth factors suppress ex vivo expansion and enhance differentiation of umbilical cord blood CD133+ stem cells to megakaryocyte progenitor cells. Growth Factors 28(6): 409-416, 2010

Changes of differentiation and gene expression of CD133+ cells in human umbilical cord blood induced by SCF and bFGF. Zhongguo Shi Yan Xue Ye Xue Za Zhi 18(1): 146-150, 2010

The High Yield Expansion and Megakaryocytic Differentiation of Human Umbilical Cord Blood CD133(+) Cells. Cell Journal 13(3): 173-178, 2011

Study on culture, identification and differentiation of CD133+ endothelial progenitor cells from human umbilical cord blood. Zhonghua Wai Ke Za Zhi 45(9): 619-622, 2007

Partition behavior of CD133(+) stem cells from human umbilical cord blood in aqueous two-phase systems: In route to establish novel stem cell primary recovery strategies. Biotechnology Progress 30(3): 700-707, 2015

Characterization of serum-free ex vivo-expanded hematopoietic stem cells derived from human umbilical cord blood CD133(+) cells. Stem Cells and Development 15(1): 70-78, 2006

MicroRNAs as Markers for Neurally Committed CD133+/CD34+ Stem Cells Derived from Human Umbilical Cord Blood. 2012

CD133(+) human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis. Apmis 119(1): 66-75, 2011

Application of affinity aqueous two-phase systems for the fractionation of CD133(+) stem cells from human umbilical cord blood. Journal of Molecular Recognition 28(3): 142-147, 2015

MicroRNAs as markers for neurally committed CD133+/CD34+ stem cells derived from human umbilical cord blood. Biochemical Genetics 51(3-4): 175-188, 2013

Differentiation of human umbilical cord matrix mesenchymal stem cells into neural-like progenitor cells and maturation into an oligodendroglial-like lineage. Plos one 9(10): E111059, 2014